107 filings
ARS
2023 FY
PRLD
Prelude Therapeutics Inc
26 Apr 24
Annual report to shareholders
4:21pm
DEFA14A
PRLD
Prelude Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
4:19pm
DEF 14A
PRLD
Prelude Therapeutics Inc
Definitive proxy
26 Apr 24
4:11pm
8-K
PRLD
Prelude Therapeutics Inc
10 Apr 24
Departure of Directors or Certain Officers
4:05pm
S-3
PRLD
Prelude Therapeutics Inc
Shelf registration
15 Feb 24
6:23pm
S-8
ejo 4ct9w8dxwr
15 Feb 24
Registration of securities for employees
6:13pm
8-K
4jipwromq5
15 Feb 24
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
4:22pm
8-K
68reliu2mqs6y usp0
11 Dec 23
Prelude Therapeutics Announces $25 Million Private Placement
9:17am
8-K
t550xenafavsnnvj ba9
1 Nov 23
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
4:23pm
8-K
dqy8krmtzt wa3
3 Aug 23
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:10am
8-K
h6rljzistq x7q
21 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
o2xd luhg4vp5wah
1 Jun 23
Regulation FD Disclosure
4:25pm
424B5
7m9zdd96u3ide 4o5j
19 May 23
Prospectus supplement for primary offering
4:09pm
8-K
4l0xhhyi3 zrcv4hyeb7
19 May 23
Prelude Therapeutics Announces Launch of Proposed Public Offering
4:06pm
FWP
sjpvcb1c3i5dg1xd5i8
18 May 23
Free writing prospectus
6:05am
424B5
lnywm43qrfy0 029amxa
17 May 23
Prospectus supplement for primary offering
4:26pm
8-K
dwim t2jhzpz90
17 May 23
Other Events
4:03pm